Drug updated on 9/24/2024
| Dosage Form | Injection (subcutaneous; 1,875 mg atezolizumab and 30,000 units hyaluronidase/15 mL) |
| Drug Class | Programmed death-ligand 1 (PD-L1) blocking monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.
- Indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.
- Indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- Indicated in combination with paclitaxel protein-bound and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- Indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq Hybreza.
- Indicated in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
- Indicated in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
- Indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
Latest News
Summary
- Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is used to treat a range of cancers, including ASPS, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and BRAF V600 mutation-positive melanoma. It is indicated for patients with unresectable or metastatic cancers and is often used in combination with other therapies, such as chemotherapy or targeted drugs like bevacizumab. For NSCLC, its use is dependent on PD-L1 expression levels and the absence of EGFR or ALK genomic tumor aberrations.
- This summary is based on the review of 36 systematic review(s)/meta-analysis(es). [1-37]
- Atezolizumab plus bevacizumab (atezo-bev) in advanced hepatocellular carcinoma (HCC) demonstrated a pooled overall survival (OS) of 13.8 months and progression-free survival (PFS) of 6.86 months. A separate study reported a median OS of 14.7 months and median PFS of 6.66 months.
- Objective response rate (ORR) for atezo-bev in advanced HCC was 26.7% using RECIST criteria and 34% using mRECIST criteria. Long-term therapy response showed an ORR of 26%, and short-term response showed 13%.
- Atezolizumab plus bevacizumab showed longer PFS and higher ORR compared to tyrosine kinase inhibitors (TKIs) in advanced HCC. However, in a study comparing atezo-bev with lenvatinib (LEN), there was no significant difference in PFS (adjusted hazard ratio [aHR]: 1.06).
- In advanced HCC, patients with Child-Turcotte-Pugh (CTP)-B cirrhosis had shorter PFS compared to those with CTP-A cirrhosis when treated with atezo-bev. In NSCLC, atezolizumab monotherapy showed improved OS (HR 0.77) compared to chemotherapy and may be preferable for patients with high PD-L1 expression.
- In advanced hepatocellular carcinoma (HCC), 83% of patients experienced any grade adverse events (AEs), with 30% experiencing grade 3 or higher AEs when treated with atezolizumab plus bevacizumab (atezo-bev).
- The incidence of grade ≥3 AEs was comparable between patients with Child-Turcotte-Pugh (CTP)-A and CTP-B cirrhosis (odds ratio [OR], 0.89) and between those receiving atezo-bev and tyrosine kinase inhibitors (TKIs) (OR, 0.86).
- In non-small cell lung cancer (NSCLC), treatment-related adverse events were significantly lower in the atezolizumab group compared to the docetaxel group (relative risk [RR] = 0.65).
- Studies on advanced HCC treated with atezolizumab plus bevacizumab (atezo-bev) focused on patients with Child-Turcotte-Pugh (CTP) cirrhosis, highlighting similar ORR but shorter PFS in CTP-B patients compared to CTP-A; in NSCLC, atezolizumab monotherapy may be preferable for patients with high PD-L1 expression, showing fewer grade ≥3 adverse events compared to combination therapy.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) Prescribing Information. | 2024 | Genentech, Inc., South San Francisco, CA |